Aligos Therapeutics (ALGS) Stock
Clinical stage biotech developing liver and viral treatments. Here's the price, business snapshot, and what's worth knowing about Aligos Therapeutics in July 2026.
Aligos Therapeutics (ALGS) is a clinical-stage biotechnology company developing therapies focused on liver and viral diseases, notably programmes addressing chronic hepatitis B and related conditions. As a small-cap, research-led company (market cap around $64.5m), its value is driven largely by clinical trial progress, regulatory milestones and potential partnerships or licensing deals rather than current revenue. Investors should expect high volatility and binary outcomes: positive clinical data or approvals can materially re-rate the stock, while setbacks can lead to sharp declines. Common risks include lengthy development timelines, regulatory uncertainty and the potential need to raise capital, which can dilute shareholders. For those tracking ALGS, keep an eye on trial readouts, pipeline updates, cash runway and collaboration announcements. This information is general and educational, not personalised investment advice — potential investors should consider their risk tolerance and seek independent financial advice where appropriate.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Aligos Therapeutics' stock with a target price of $65, indicating strong growth potential.
Financial Health
Aligos Therapeutics is managing cash and revenue reasonably well, but growth potential appears limited.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring ALGS
Liver Disease Therapies | Next-Gen FDA Approvals
The FDA's recent accelerated approval of Gilead's Hepcludex has established the first legal treatment for a deadly liver infection known as hepatitis D. This milestone opens the door for investors to explore opportunities in companies developing innovative liver disease therapies, specialized diagnostics, and advanced patient monitoring systems.
Published: 26 May 2026
Explore BasketNext-Gen Hepatic Therapeutics | Basket Overview
The FDA has granted Gilead Sciences approval for the first-ever treatment targeting chronic hepatitis delta virus. This landmark regulatory decision paves the way for further investments in biotechnology companies developing novel therapeutics for rare and complex liver diseases.
Published: 24 May 2026
Explore BasketAntiviral M&A Wave: Biotech Opportunities in 2025
Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.
Published: 16 November 2025
Explore BasketPharma M&A Targets (Metabolic Disease Biotechs)
Novo Nordisk's $5.2 billion acquisition of Akero Therapeutics highlights a strategic push into the MASH treatment market. This deal could trigger a wave of similar acquisitions, boosting the value of other biotech firms with promising drugs for metabolic diseases.
Published: 10 October 2025
Explore BasketMASH Stocks: Could Roche's Deal Spark More M&A?
Roche's $3.5 billion acquisition of 89bio for its liver disease drug highlights the growing MASH treatment market. This deal creates a potential tailwind for other biopharmaceutical companies developing therapies for liver and metabolic conditions.
Published: 21 September 2025
Explore BasketMASH Drug Developers Could Attract M&A in 2025
Roche's $3.5 billion deal to acquire 89bio for its late-stage liver disease drug highlights the immense commercial potential seen in the MASH treatment landscape. This move could trigger a wave of investment and further acquisitions, benefiting other biotech firms with promising therapies for metabolic disorders.
Published: 19 September 2025
Explore BasketMASH Biotech Stocks: What's Next After Roche Deal
Roche's acquisition of 89bio for its late-stage liver disease drug highlights a major strategic investment in the MASH treatment space. This move could increase the valuation of other biotech companies developing therapies for metabolic disorders as they become attractive M&A targets.
Published: 18 September 2025
Explore BasketWhich Pharma Stocks Could Follow Wegovy's Success?
Following the FDA's approval of Novo Nordisk's Wegovy for a common liver disease, this theme focuses on pharmaceutical companies developing treatments for metabolic disorders. This development opens a new market for weight-loss drugs and signals opportunity for firms with therapies targeting related conditions.
Published: 21 August 2025
Explore BasketGLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Published: 19 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage drug programmes
Pipeline progress and trial readouts drive value, so milestones can create strong share movements — though outcomes can be binary and unpredictable.
Upcoming catalysts and milestones
Regulatory decisions, trial data and partnership news are likely catalysts to watch; these events can lead to rapid gains or losses.
Cash position and dilution
As a small-cap biotech, monitoring cash runway and fundraising plans is important because additional capital raises can dilute shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
